Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 16/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2136163 | 0.77 | CHRM5 (0.44) | P2RX3 | |
| SCHEMBL2131794 | 0.76 | KDM4E (0.45) | P2RX3KMT2A | |
| SCHEMBL2130801 | 0.75 | EGLN1 (0.47) | P2RX3MEN1KMT2AEGLN1 | |
| SCHEMBL2131801 | 0.71 | HCRTR1 (0.48) | P2RX3 | |
| SCHEMBL7224799 | 0.69 | ALDH1A1 (0.41) | — | |
| SCHEMBL5963434 | 0.68 | L3MBTL1 (0.49) | MEN1KMT2A | |
| SCHEMBL745312 | 0.66 | HCRTR2 (0.63) | MEN1KMT2A | |
| SCHEMBL10134383 | 0.66 | MEN1 (0.83) | P2RX3MEN1KMT2A | |
| SCHEMBL4797268 | 0.64 | MEN1 (0.59) | P2RX3MEN1KMT2A | |
| SCHEMBL851116 | 0.64 | MEN1 (0.59) | P2RX3MEN1KMT2AEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329706-B2 | Oxazolidinone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-12-11 | — | — | US | disclosed |
| US-20120101111-A1 | NOVEL OXAZOLIDINONE DERIVIATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101111-A1 | NOVEL OXAZOLIDINONE DERIVIATIVES | HCRTR2, HCRTR1, NPY4R | P2RX3 206/4885MEN1 949/4885KMT2A 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.